Retatrutide

Overview

Retatrutide (also referred to as GLP-3 or LY3437943) is a synthetic peptide engineered as a triple agonist of the GLP-1, GIP, and glucagon receptors. It was developed as a research tool to investigate the combined activation of three incretin and metabolic-hormone pathways within a single molecule.

Research Background

Preclinical and early clinical research has examined Retatrutide as part of a class of multi-receptor incretin agonists, with studies focusing on energy balance, lipid and glucose metabolism, and adipose tissue regulation. Its triple-agonist profile distinguishes it from earlier dual-receptor peptides such as Tirzepatide.

Storage & Handling

Store lyophilized peptide at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within recommended timeframes. Handle under sterile laboratory conditions and avoid repeated freeze-thaw cycles.

Disclaimer:
This product is for laboratory research use only. It is not intended for human or animal consumption or for use in any diagnostic, therapeutic, or clinical applications.

Retatrutide simultaneously engages three receptors involved in metabolic regulation: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Activation of GLP-1 and GIP receptors influences insulin secretion and gastric motility pathways, while glucagon receptor engagement is studied in connection with hepatic glucose output and energy expenditure. The combined receptor activity is the basis for its classification as a triple incretin agonist.

Retatrutide is studied in research models examining glycemic regulation, lipid metabolism, body composition, and energy expenditure. Its multi-receptor profile is of interest to investigators exploring next-generation incretin pharmacology beyond single- and dual-agonist approaches.